Supplementary material to article by J. H. O. Hoffmann et al. "Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles"

Table SIII. Statistical performance of selected Psoriasis Area and Severity Index (PASI) thresholds to predict low cardiovascular risk C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) depending on the treatment duration

	PASI 0				PASI 2.75			
	< 3 months	3-6 months	6-12 months	≥12 months	< 3 months	3-6 months	6-12 months	≥12 months
CRP < 3 mg/l								
Sensitivity	3%	15%	24%	35%	23%	57%	73%	76%
Specificity	99%	93%	86%	89%	87%	57%	56%	46%
Positive predictive value	82%	78%	77%	89%	72%	69%	76%	77%
NLR < 2.15								
Sensitivity	3%	11%	22%	31%	23%	54%	69%	72%
Specificity	98%	87%	81%	77%	84%	53%	48%	33%
Positive predictive value	45%	56%	68%	67%	52%	62%	71%	62%
CRP < 3 mg/l and NLR < 2.15								
Sensitivity	4%	14%	23%	37%	25%	56%	73%	76%
Specificity	98%	89%	82%	80%	85%	53%	47%	37%
Positive predictive value	50%	48%	53%	63%	47%	47%	56%	52%

Acta Derm Venereol 2021